Search
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Categories: Heterocyclic Compounds, 1-RingN-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalN-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group. … It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated.
Mixtures: Aminosyn II 7% With 50% Dextrose, Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Synonyms: L-N-acetyltyrosine, N-acetyl-L-tyrosineMilbemycin oxime
go.drugbank.com/drugs/DB11531ExperimentalVet approvedMixtures: Nexgard Spectra 9mg/2mg Chewable Tablets for Dogs 2-3.5kg, Nexgard Spectra 38mg/8mg Chewable Tablets for Dogs >7.5-15kgBB 21217
go.drugbank.com/drugs/DB17373InvestigationalBB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP … ) for memory-like T cells.
ABP-700
go.drugbank.com/drugs/DB15411InvestigationalABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy
Categories: GABA-A Receptor Agonists, Heterocyclic Compounds, 1-RingNomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnApproval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)).
Synonyms: D,L-nomifensine, 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamineCategories: Heterocyclic Compounds, 2-RingCediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Categories: Heterocyclic Compounds, 2-RingNGX267
go.drugbank.com/drugs/DB05152InvestigationalNGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Categories: Heterocyclic Compounds, 1-RingVelusetrag
go.drugbank.com/drugs/DB12702InvestigationalIt is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. … Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders.
Daleuton
go.drugbank.com/drugs/DB00154InvestigationalNutraceuticalA 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
Synonyms: 20:3, n-6,9,12 all-cis, (Z,Z,Z)-8,11,14-Icosatrienoate